Nicholas Mai

10PUBLICATIONS
45CO-AUTHORS
Molecular targetsClinical midwiferyCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 09, 2026
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.

|Dec 02, 2025
Precision Oncology: 2025 in Review.

Nicholas Mai, Nicole Fernandez, Alexander Drilon

|Nov 10, 2025
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.

Wanyi Chen, Avantika Gupta, Nicholas Mai

|Jul 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Jacob A Boyer, Ezra Y Rosen, Malvika Sharma

|May 29, 2025
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.

|Oct 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.

Nicholas Mai, Carlos H Dos Anjos, Pedram Razavi

Pageof 2

Frequent Collaborators

7 joint publications

Sarat Chandarlapaty

5 joint publications

Pedram Razavi

3 joint publications

Shanu Modi

3 joint publications

Joshua Z Drago